Actively Recruiting

Age: 18Years +
All Genders
ID05438537

A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)

Led by Chinese University of Hong Kong · Updated on 2024-01-23

300

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Upper Tract Urothelial Cancer (UTUC) is a relatively uncommon but increasingly diagnosed condition with many controversies and limitations in its management. Researchers aim to create a local registry at their hospital to gather detailed clinical information and outcomes related to UTUC, helping to better understand the disease's epidemiology, natural history, and treatment results. This study is observational and focuses on collecting comprehensive data to improve knowledge and care for UTUC patients. Participants in this study will be adults diagnosed with UTUC who are either awaiting surgery or have a history of UTUC with prior interventions. The study involves collecting blood, urine, and tumor tissue samples to explore new diagnostic and therapeutic possibilities. There is no specific treatment given as part of this study; rather, it tracks patients over time to assess the disease and its effects. Participants will be followed for up to 10 years to monitor long-term survival, recurrence rates, disease progression, and any complications related to UTUC. The study includes regular collection of clinical information and biological samples to support these assessments. This long-term observation aims to provide valuable insights into the physical and biological impact of UTUC on patients.

CONDITIONS

Brief Title

A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male patients older than 18 years
  • Patients diagnosed with Upper Tract Urothelial Cancer and scheduled for surgery
  • Patients with a history of Upper Tract Urothelial Cancer who have had any intervention
Not Eligible

You will not qualify if you...

  • Patients unable to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery

Duration - Varies depending on individual treatment schedules

Participants undergo surgery as part of their treatment for Upper Tract Urothelial Cancer.

Scheduled surgical visits

Long-term Monitoring

Duration - Up to 10 years

Participants are monitored for long-term survival, recurrence, progression, and complications related to Upper Tract Urothelial Cancer.

Regular follow-up visits as per clinical care

Trial Site Locations

Total: 1 location

1

Prince of Wales Hospital

Hong Kong, Hong Kong

Actively Recruiting

Loading map...

Research Team

J

Jeremy Yuen-Chun TEOH, FRCS(Ed)

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Prospective Evaluation of DNA Repair Gene Alterations to Pre...

Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

Actively Recruiting

1 location

A Phase II Trial of Sequential Gemcitabine and Mitomycin Tre...

Urinary Bladder Cancer

Actively Recruiting

1 location

Single-Port Robot-Assisted Surgery Using Da Vinci SP Surgica...

Upper Tract Urothelial Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Trends in epidemiology and treatment of upper urinary tract tumours in the Netherlands 1995-2005: an analysis of PALGA, the Dutch national histopathology registry.

Evelyne C C Cauberg, Maartje A Salomons, Intan P E D Kümmerlin...

https://pubmed.ncbi.nlm.nih.gov/19804428

Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.

Giovanni Lughezzani, Maximilian Burger, Vitaly Margulis...

https://pubmed.ncbi.nlm.nih.gov/22381168